Philips presents study results at Heart Rhythm Annual Meeting demonstrating benefits of its AI-powered cardiac monitoring solutions
2024年5月17日 - 5:00PM
May 17, 2024
Three studies demonstrate how Philips MCOT wearable ambulatory
monitoring ECG and proprietary AI models applied to ECG digital
biomarkers can help to improve diagnosis, reduce readmissions, and
lower costs
Amsterdam, the Netherlands and Boston, USA
– Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in
health technology, is presenting new retrospective study results
demonstrating the clinical and economic benefits of Philips’
AI-powered cardiac care solutions at the Heart Rhythm Annual
Meeting in Boston (May 16-19).
With cardiovascular disease on the rise, clinicians and health
systems continue to look for ways to deliver high-quality care that
is both timely and cost-effective. Findings from the three studies
highlight the central role mobile cardiac monitoring technology
plays in supporting early detection of adverse cardiac events and
enabling potentially life-saving interventions for patients, while
helping to reduce readmissions and lower costs.
Recently published in The Journal of Comparative Effectiveness
Research, a Philips study compares the clinical and economic
outcomes of using the Philips mobile cardiac outpatient telemetry
(MCOT) wearable ECG sensor with implantable loop recorders (ILRs)
in stroke patients to determine how cardiac remote monitoring
technology impacts current standards of care. This study analyzed
the eighteen months following a stroke event and found that when
MCOT was used instead of ILR for post-discharge monitoring:
- Patients experienced significantly lower readmissions (30.2% in
the MCOT-monitored group compared to 35.4% in the ILR group);
- Average cost over an 18-month period following the stroke event
was reduced by USD 27,429;
- Emergency department utilization was significantly lower;
- Patients with complications and comorbidities from the index
stroke experienced a higher rate of survival.
Manish Wadhwa, Chief Medical Officer for Philips Ambulatory
Monitoring & Diagnostics, said: “As we explore how specific
ambulatory monitoring devices, like MCOT, impact clinical outcomes,
data demonstrates that choice of monitoring modality does affect
the cost-effectiveness of care and patient outcomes. Effective
cardiac monitoring starts with quality data, and with the
AI-powered data platform behind MCOT, Philips is uniquely
positioned to help care teams make quick, impactful, and
cost-conscious decisions for their cardiac patients.”
On Saturday, May 18 at 3 p.m., Philips will host a moderated
discussion about the comparative outcomes and cost of ILR and MCOT
following stroke with electrophysiologist Dr. Mohammad-Ali Jazayeri
in booth #1135.
Two poster presentations will highlight additional recent
research showcasing Philips’ impact on improved health outcomes and
AI-driven diagnosis:
- Back to the Future: Artificial intelligence applied to
ECG can help identify life-threatening arrhythmia events at the
rootsThe cause of syncope, a loss of consciousness or
fainting, is difficult to diagnose and the condition leads to
approximately 3% of all visits to the emergency room. Syncope may
be caused by a serious heart condition and cardiac monitoring
solutions are often used to detect adverse heart rate and/or rhythm
events to improve how syncope patients are diagnosed and managed.AI
and deep neural network (DNN) algorithms have demonstrated the
ability to provide accurate medical diagnoses equivalent to human
physicians or conventional algorithms. Philips’ study reveals that
AI-powered ECG biomarker technology may help to identify patients
with significant intermittent bradyarrhythmia, potentially
improving timely diagnosis and management. Using an AI-based
learning model, the study focused on successfully triaging syncope
patients by identifying those who had previously experienced
bradyarrhythmia.Dr. Laurent Fiorina, Cardiovascular Institute
Paris-Sud (ICPS) and medical advisor for Philips, said: “Our main
focus is developing new AI models to detect cardiovascular
conditions or predict future cardiac events like atrial
fibrillation, ventricular tachycardia, and now, severe
bradyarrhythmia.”Join Dr. Fiorina and Philips between 3:30 and 5:30
p.m. ET on Friday, May 17 in the HRS Abstract area to learn more
about this study and its impact on the future of cardiac care.
- The EP-COT Trial: Impact of Emergent Physician
Notifications from MCOT on Patient OutcomesWhile
ambulatory cardiac monitors are frequently used to diagnose
arrhythmias, their impact on clinical decision-making has not been
extensively studied. When examining how MCOT impacts acute clinical
management decisions, Dr. David Lin at the University of
Pennsylvania and Dr. Mathew Hutchinson at the University of Arizona
found that patients who had Emergent Notifications while wearing a
Philips MCOT had a high degree of symptom-arrhythmia correlation
and that these notifications were delivered to the care provider.
The notifications initiated unscheduled follow-up care in over 85%
of patients and a procedural intervention in over 25%, indicating
MCOT’s effectiveness in detecting actionable arrhythmias and
enabling care teams to intervene and provide necessary care.Dr.
David Lin, Cardiologist at the University of Pennsylvania Hospital,
will present these trial findings in further detail in the HRS
Abstract Area between 3:30 and 5:30 p.m. ET.
Lead Management and CIED Infection Philips will
also continue to educate on cardiac implantable electronic device
(CIED) infections to improve the quality of patient care by
ensuring physicians are knowledgeable about CIED infection
treatment and guidelines. Philips supports physicians with
Lead Management solutions through a broad portfolio of tools
designed for safety and predictability, including both laser and
mechanical lead extraction devices to help indicated patients get
the quick and effective treatment they deserve.
On Friday, May 17th, Philips will host a Rhythm Theater in
partnership with Medtronic on the prevention, identification, and
management of CIED infections in Rhythm Theater #1 at 11:00 am
ET.
Additional details on clinical presentations at the show on
behalf of Philips can be viewed here. For more information on
Philips’ presence at HRS, join in person at booth #1135 in the
Boston Convention and Exhibition Center or visit Heart Rhythm 2024.
Follow #HRS2024 for updates throughout the event.
For further information, please contact:
Meredith AmorosoPhilips External RelationsTel: +1
724-584-8991E-mail: meredith.amoroso@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being through meaningful
innovation. Philips’ patient- and people-centric innovation
leverages advanced technology and deep clinical and consumer
insights to deliver personal health solutions for consumers and
professional health solutions for healthcare providers and their
patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
ultrasound, image-guided therapy, monitoring and enterprise
informatics, as well as in personal health. Philips generated 2023
sales of EUR 18.2 billion and employs approximately 69,100
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- A cardiologist reviews an ECG readout report with AI-assisted
analysis
Koninklijke Philips NV (NYSE:PHG)
過去 株価チャート
から 5 2024 まで 6 2024
Koninklijke Philips NV (NYSE:PHG)
過去 株価チャート
から 6 2023 まで 6 2024